Balaxi Pharmaceuticals recently performed the groundbreaking ceremony of its US-FDA, EU-GMP, WHO-Geneva Compliant Pharmaceutical Formulation Plant at Jadcherla Mandal, Telangana.

The company will be investing Rs 85 crore in the state-of-the-art facility over a period of one year that will enable them to enter European markets as well as enhance margins in current markets.

To drive this initiative forward, Mumbai-based consultant Spectrum Pharmatech Consultant has been appointed for the smooth and time bound project execution.

The plant will provide direct and indirect employment to approximately 350+ individuals. This facility is housed across approximately 1,50,000 square feet, with a capacity of 1 billion tablets per annum, 500 million capsules per annum, and 27 million liquid injections per annum.

The plant’s proposed completion is scheduled for March 2024 and will be abundantly equipped to cater to the demands of global markets. Adhering to global standards for products and services, production from its planned facility will find immediate traction from established demand in existing markets. The robust production will allow backward integration of its supply chain and is expected to start by June 2024.